Board of Directors

Mr. Krupik is the chief executive officer for CBI and responsible for defining the vision, strategy and direction of CBI. Mr. Krupik is an active chairman at D-pharm, CureTech, Mediwound and Andromeda. An accomplished, multi-disciplinary industry executive and visionary, Mr. Krupik was a key driver in the launch of numerous successful companies in the fields of medical technology (Given Imaging, Galil Medical), image processing (3DV), broadband and software. With a wide-ranging entrepreneurial track record, he is well versed in the complex processes and aspects of transforming promising ideas into thriving companies. A master of the art of harnessing investment capital to technology in order to weave commercial achievements, Mr. Krupik was highly instrumental in the foundation of Rafael Development Corporation (RDC), a joint venture of Rafael (a technological division of the Israeli Ministry of Defense) and a group of large investment corporations. He served as president and CEO of RDC, which specializes in identifying commercially viable technologies within Rafael and forming start-up companies around them. Mr. Krupik held several senior positions at Tadiran Telecommunication Group where he accrued extensive experience in high-tech management. Ruben holds an LLB from the Faculty of Law of the Tel Aviv University and B.A.s in economics and political science both from the Hebrew University of Jerusalem.

Mr. Zisser is the executive president of Elbit Imaging, where he also served as executive chairman of the Board of Directors from 1999-2009. Mr. Zisser has served as president and chairman of the board of directors of Europe-Israel since March 1998, and president and chairman of the board of directors of Control Centers since 1983. He has developed major real estate development projects in Israel (including the city of Emmanuel, the Herzliya Marina, the Ashkelon Marina, and the Sea and Sun luxury residential project in north Tel Aviv), as well as large scale residential and hotel projects abroad. As president of Elbit Imaging, Mr. Zisser leads the company’s core businesses, including real estate investment, hotel ownership and management, development and operation of shopping and entertainment centers in Central/Eastern Europe and in India, development of major residential projects and mixed-use complexes as well as venture capital investments in the hi-tech, medical and bio-technology industries. Mr. Zisser has also served as executive chairman of the board of directors of Plaza Centers since October 2006. Mr. Zisser is active in charitable organizations and is a member of the management of the “Oranit” hostel.

Dr. Hadar Ron is the managing director of Israel Healthcare Ventures, Ltd. (IHCV), a venture capital fund focused on investing in Israeli and Israel related companies in the field of medical devices, biotechnology, pharmaceutical and medical-related IT. Dr. Ron is a physician and attorney. She has extensive medical, legal and management experience gained while serving in senior positions at a range of insurances companies, law firms, medical and educational institutions. Her legal and management expertise includes venture capital consulting, medical malpractice, general and medical insurance and legal practice. In the medical field, Dr. Ron has spearheaded several research initiatives and has developed and taught courses on medical law. Dr. Ron is very familiar with the field of medical product development, the processes associated with their approval by relevant authorities and marketing to customers, and the steps required of developing companies for achieving their business objectives. She is an experienced member of boards of directors of numerous medical companies. Dr. Ron holds MD and LLB degrees from Tel Aviv University and has studied at the School of Business Administration at Tel Aviv University and in advanced courses at Boston University School of Medicine.

Noam Karstaedt has been an active manager in the Israeli venture capital industry since his partnership in Medmax Ventures, the first dedicated life science VC fund focused on Israeli startups which began investing in 1992. In 1998 he raised and managed a second fund, Denali Ventures which was an early investor in Gamida Cell. He has held management and consulting positions in Israel and the United States including a period in San Francisco with management consultants Booz, Allen and Hamilton. Mr. Karstaedt has a masters in chemical engineering from the University of the Witwatersrand, Johannesburg South Africa and an MBA from the Graduate School of Business, Stanford University, California.

Dr. Margolin has served on the Board of Directors of Gamida Cell since 2000. Prior to her employment as president & CEO of Gamida Cell, Dr. Margolin spent six years as vice president of Denali Ventures LLC, where she specialized in investments in pharmaceutical and biotechnology companies. Dr. Margolin also worked for seven years at Teva Pharmaceuticals, where she was responsible for new product initiatives, evaluation of investment opportunities for the R&D division, and multiple drug development programs. Dr. Margolin holds a Ph.D. in Biochemistry from the Weizmann Institute of Science and was a post-doctoral associate at the Yale University School of Medicine.